Financial Data and Key Metrics Changes - For Q4 2025, Embecta generated $264 million in revenue, reflecting a 7.7% decline year-over-year on an as-reported basis or a 10.4% decline on an adjusted cost and currency basis [10][11] - GAAP gross profit for Q4 2025 totaled $158.5 million with a margin of 60%, compared to $173.8 million and 60.7% in the prior year [15] - Adjusted net income for Q4 2025 was $29.4 million, up from $25.9 million in the prior year, with adjusted diluted earnings per share at $0.50 compared to $0.45 [17][20] Business Line Data and Key Metrics Changes - In Q4 2025, U.S. revenue totaled $142 million, reflecting a year-over-year decline of 15.2% on an adjusted cost and currency basis, primarily due to unfavorable comparisons from the previous year [11][12] - International revenue for Q4 was $122 million, representing a 2.8% increase on a reported basis but a decline of 4% on an adjusted cost and currency basis, driven by lower volumes and pricing headwinds in China [12][13] - For the full year, pen needle revenue declined approximately 7.1% to $784.1 million, while safety products grew 6.3% due to improved pricing and volume increases [14][19] Market Data and Key Metrics Changes - The decline in international revenue was primarily attributed to lower contributions from China, influenced by heightened competitive intensity and local brand preferences [12][14] - The company anticipates launches of generic GLP-1 products in Canada, Brazil, and India during Calendar Year 2026, which could represent a significant revenue opportunity [8][35] Company Strategy and Development Direction - The company ended its Patch Pump Program and executed a restructuring plan to enhance profitability and free cash flow, generating approximately $182 million in free cash flow and paying down $184 million of debt in FY 2025 [5][9] - Embecta is focusing on advancing its GLP-1 strategy, collaborating with over 30 pharmaceutical partners to co-package pen needles with generic GLP-1 therapies, aiming for a $100 million annual revenue opportunity by 2033 [7][35] - The company is prioritizing financial discipline and debt reduction while exploring organic and inorganic growth opportunities [9][64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's direction despite a complex geopolitical and trade backdrop, emphasizing the importance of maintaining leadership in core categories and advancing innovation programs [75] - The initial guidance for FY 2026 anticipates flat to down 2% revenue compared to 2025 levels, with expectations of modest volume declines in core injection business [22][24] Other Important Information - The company completed the implementation of its ERP system and operationalized a new distribution network in Latin America and India, marking a significant milestone in its strategic roadmap [5][10] - A recent agreement to sell certain intellectual property rights associated with the discontinued Patch Pump Program for $10 million is expected to increase cash flow but will not impact adjusted results [21][68] Q&A Session Summary Question: Details on GLP-1 partnerships - Management is in discussions with over 30 potential GLP-1 partners, with several already providing orders for development purposes, and anticipates commercial launches in 2026 [33][34] Question: Consumer willingness to buy non-Chinese products in China - Management noted that Q4 2025 performance in China met expectations, and steps have been taken to stabilize the situation, including introducing a more price-competitive pen needle [38][39] Question: Increased cannula costs and sourcing alternative suppliers - The company is working on identifying alternate cannula suppliers to mitigate increased costs from the sole-source agreement with BD, which is expected to last until 2032 [44][46] Question: Clarification on milestone payments to a U.S. pharmacy customer - Management explained that milestone payments are tied to contract terms, including rebates and marketing spend, which can lead to year-over-year price fluctuations [49][50] Question: Structure of contracts with generic GLP-1 providers - Management indicated that initial contracts focus on quality agreements and vendor qualification, with commercial contracts to be discussed once generic manufacturers receive approval [55][56]

Financial Data and Key Metrics Changes - In Q3 2025, the company achieved record revenue of $295.5 million, reflecting an 8.4% growth on a reported basis and 8% on an adjusted constant currency basis [11][12] - GAAP gross profit was $197.1 million with a margin of 66.7%, compared to $190.1 million and 69.8% in the prior year [17] - Adjusted net income for Q3 2025 was $65.5 million, or $1.12 per diluted share, up from $43 million and $0.74 in the prior year [19] Business Line Data and Key Metrics Changes - Pen needle revenue grew approximately 6.8%, syringe revenue increased by 14.5%, safety products grew by 6.5%, and contract manufacturing surged by 47.2% [14] - The increase in syringe revenue was primarily driven by higher pricing, while pen needle volumes were supported by favorable comparisons to the prior year [14][15] Market Data and Key Metrics Changes - Revenue from the US totaled $160.2 million, representing year-over-year growth of 11.6% on an adjusted constant currency basis [12][13] - International revenue reached $135.3 million, reflecting a growth of 5% on a reported basis, primarily driven by Latin America and Asia [13] Company Strategy and Development Direction - The company is focused on strengthening its core business, expanding its product portfolio, and enhancing financial flexibility [6][10] - A significant transition from BD to Ambecta branded products in North America has been completed, with over 90% of the revenue base converted [7] - The company is collaborating with over 30 pharmaceutical companies to co-package pen needles with generic GLP-1 therapies, with potential commercialization starting in 2026 [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to generate strong free cash flow and achieve debt reduction targets, having already paid down $112 million year-to-date [20][21] - The company anticipates a decline in revenue for Q4 due to the reversal of timing benefits and a less favorable comparison to the prior year [28][29] Other Important Information - The company has completed its multi-year ERP program, which is expected to enhance operational efficiency [6][10] - The updated financial guidance for 2025 includes a revenue range of $1.078 billion to $1.085 billion, reflecting a decline of 3.4% [23] Q&A Session Summary Question: Guidance on revenue dynamics for Q4 - Management indicated that Q4 revenue is expected to decline to around $265 million, primarily due to the absence of distributor orders and the reversal of rebate reserve adjustments [28] Question: Margin expectations for Q4 - Management noted that a decline in gross and operating margins is typical from Q3 to Q4, with expected operating margins around 24% for Q4 [31] Question: Capital allocation and share repurchase interest - Management reiterated that debt repayment remains a priority, with no immediate plans for share buybacks [37] Question: Impact of competitive bidding proposal from CMS - Management acknowledged potential positive impacts on the pen needle business but emphasized the uncertainty surrounding the proposal's effects on pump adoption rates [41] Question: Tariff impacts and demand in China - Management stated that minimal incremental tariff impacts are expected, with a preference for local brands observed in the Chinese market [44][45] Question: Free cash flow generation outlook - Management highlighted strong free cash flow capabilities, with $81 million generated in Q3, indicating a positive trajectory towards achieving long-term targets [50] Question: Store closures and market dynamics - Management is monitoring the impact of store closures on performance, noting that patients may be shifting to other pharmacies [52]